New brain scan could sharpen surgery for glioma patients
NCT ID NCT01165632
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This pilot study tested whether a special PET scan using 18F-FDOPA can help doctors better plan surgery and radiation for people with newly diagnosed brain tumors (gliomas). Twenty-four adults took part at Mayo Clinic. The goal was to see if the scan provides useful information beyond standard MRI, not to treat the tumor itself.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 18F-FDOPA (a radioactive tracer used in PET scans)
- What this could lead to
- If successful, this could improve how doctors plan surgery and radiation for brain tumors, potentially leading to more precise treatment.
- What could go wrong
- This is a very early pilot study with only 24 participants. It is designed to gather information, not to test a treatment. The results may not change current practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
24 people
The number who actually took part.
- Started
-
Jul 2010
- Finished
-
Jul 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years. * MRI findings compatible with newly diagnosed high- or low-grade malignant glioma * Planned craniotomy and resection or biopsy * Willing to sign release of information for any radiation and/or follow-up records * Negative pregnancy test done =\< 48 hours of injection of study drug, for women of childbearing potential only * Provide informed written consent * Patients with eGFR \< 60 mg/min/1.72m2 are eligible for the study; PLEASE NOTE: the patient is not eligible to receive the contrast for the pMRI at the study dose. Exclusion Criteria: * Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure) * Unable to undergo an 18F-FDOPA PET scan (e.g. Parkinson's Disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists) * Pregnant women; nursing women; men or women of childbearing potential who are unwilling to employ adequate contraception
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adult anaplastic astrocytoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could dropping one chemo drug improve life for young brain tumor patients?
- Brain surgery safety: live signal monitoring may shield speech, movement, and sight
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?